NBTXR3

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Retrieved on: 
Monday, November 8, 2021
Biotechnology, Pharmaceutical, Health, Nasdaq, Nanotechnology, AMF, Article, Twitter, Nanobiotix, NBTXR3, LinkedIn, Central nervous system, Patient, Life, Pharmaceutical industry

(1) The total number of gross (or theoretical) voting rights is used as the basis for calculating threshold crossings.

Key Points: 
  • (1) The total number of gross (or theoretical) voting rights is used as the basis for calculating threshold crossings.
  • In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
  • (2) The total number of net (or exercisable at a Shareholders Meeting) voting rights is calculated without taking into account shares for which voting rights have been suspended.
  • The companys philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 3, 2021
Biotechnology, Health, Oncology, NBTXR3, NANO, Nanobiotix, LinkedIn, Cancer, Nanotechnology, Twitter, Patient, NASDAQ, Life, Conference, Nasdaq, Webcast, Central nervous system, Pharmaceutical industry

NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the Company), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 3:40 PM GMT / 10:40 AM EST on Tuesday, November 16, 2021.

Key Points: 
  • NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the Company), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 3:40 PM GMT / 10:40 AM EST on Tuesday, November 16, 2021.
  • The fireside chat will be webcast live from the Events section of the companys website at www.nanobiotix.com .
  • A replay of the webcast will be archived and available for one month following the event.
  • For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .

NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy

Retrieved on: 
Sunday, October 24, 2021
General Health, Health, Radiology, Clinical Trials, Oncology, NBTXR3, NANOBIOTIX, NBTXR3, NANOBIOTIX

In the full population (all evaluable and non-evaluable patients treated; n=54), data showed a 14.1-month mOS and a 9.4-month mPFS.

Key Points: 
  • In the full population (all evaluable and non-evaluable patients treated; n=54), data showed a 14.1-month mOS and a 9.4-month mPFS.
  • This first look at survival data has added to my confidence that NBTXR3 could provide a promising new therapeutic option for the practice.
  • A total of 8 Grade 3-4 NBTXR3-related adverse events (AEs) were observed in 8 patients, representing 1.3% of all observed AEs.
  • While the incidence of LA-HNSCC has continued to rise, patients in the elderly and frail LA-HNSCC population have significant unmet needs.

NANOBIOTIX Provides Third Quarter Operational and Financial Update

Retrieved on: 
Wednesday, October 20, 2021
Oncology, Health, Technology, Nanotechnology, Pharmaceutical, Biotechnology, Safety, Liver disease, Neoplasm, Twitter, Partnership, Mall of America, Lung, Radiation, Life, Nasdaq, Trial of the century, COVID-19, Company, PFS, Nanotechnology, Nanoparticle, AMF, Radiation therapy, Monroe Dunaway Anderson, Private Securities Litigation Reform Act, Biology, U.S. Securities and Exchange Commission, Cancer, Annual report, University, Investment, Nivolumab, Central nervous system, NBTXR3, Cetuximab, III, MD Anderson Cancer Center, SEC, Risk, Â, HNSCC, Population, NANO, Annual general meeting, Poster, LinkedIn, Patient, NASDAQ, Forward-looking statement, Metastasis, Canadian International Council, Pharmaceutical industry, Medical imaging, NBTXR3, NANOBIOTIX, NBTXR3, NANOBIOTIX

Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.

Key Points: 
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.
  • Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.
  • 1 It being specified that the company did not generate any revenue during the third quarter of 2021, this following the termination of the PharmaEngine partnership.

NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, HNSCC, Radiation therapy, Private Securities Litigation Reform Act, III, Population, AMF, Nanotechnology, Mall of America, ASTRO, Safety, Nanoparticle, SEC, Lung, U.S. Securities and Exchange Commission, Poster, LinkedIn, Central nervous system, Phase, Twitter, Survival, Radiation, Neoplasm, Solution, Annual report, NBTXR3, NASDAQ, Cancer, Company, Life, Risk, Forward-looking statement, Doctor of Philosophy, Society, Nivolumab, NANO, Ministry of Education (Malaysia), MD Anderson Cancer Center, Immunotherapy, Cetuximab, Trial of the century, COVID-19, Metastasis, University, Nasdaq, Pharmaceutical industry, Powder metallurgy, NBTXR3, NANOBIOTIX, NBTXR3, NANOBIOTIX

Bringing disruptive therapeutic solutions that expand treatment possibilities for patients with cancer starts with making a meaningful impact on survival, said Laurent Levy, co-founder and chairman of the executive board of Nanobiotix.

Key Points: 
  • Bringing disruptive therapeutic solutions that expand treatment possibilities for patients with cancer starts with making a meaningful impact on survival, said Laurent Levy, co-founder and chairman of the executive board of Nanobiotix.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.
  • For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.

NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

Retrieved on: 
Tuesday, September 28, 2021
Oncology, Health, Radiology, Clinical Trials, Research, Science, Biotechnology, Neoplasm, ICIS, HNSCC, Biology, Annual report, Oncology, Cancer, NBTXR3, Private Securities Litigation Reform Act, NASDAQ, III, U.S. Securities and Exchange Commission, NANO, Patient, MD Anderson Cancer Center, Monroe Dunaway Anderson, Population, MD, LinkedIn, Central nervous system, Canadian International Council, Cetuximab, Twitter, University, Company, Life, Growth, Radiation therapy, RT, Trial of the century, Nanotechnology, Mall of America, Risk, COVID-19, Forward-looking statement, Metastasis, Radiation, Safety, Nanoparticle, Nasdaq, Tumor microenvironment, Lung, Pharmaceutical industry, NBTXR3, NANOBIOTIX, NBTXR3, NANOBIOTIX

We are proud to collaborate with MD Anderson as we seek to validate the broadly applicable, local and systemic potential benefits of NBTXR3.

Key Points: 
  • We are proud to collaborate with MD Anderson as we seek to validate the broadly applicable, local and systemic potential benefits of NBTXR3.
  • Immune checkpoint inhibitors (ICIs) such as anti-PD-1 have shown tremendous promise for the treatment of some patients with metastatic tumors.
  • To date, however, most patients with cancer have shown resistance to anti-PD-1, limiting the effect of this combination.
  • NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway.

Nanobiotix Provides Second Quarter Operational and Financial Update

Retrieved on: 
Tuesday, July 20, 2021
Oncology, Professional services, Health, Other Health, Finance, Clinical trials, Biotechnology, Nanobiotix, Oncology, Cash and cash equivalents, NBTXR3, NANOBIOTIX:, NBTXR3, NANOBIOTIX:

Regulatory News:

Key Points: 
  • Nanobiotix did not generate any revenue during the second quarter of 2021.
  • Revenue for the second quarter and first half of 2020 amounted to 13.4k and 36.9k respectively.
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 102.3 million as of June 30, 2021, compared to 107.1 million as of March 31, 2021.
  • Nanobiotix plans to report half-year financial results for the six-months ended June 30, 2021, including condensed consolidated financial statements for the period, on September 8, 2021.

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

Retrieved on: 
Wednesday, June 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cancer treatments, Medicine, Nanobiotix, Oncology, Breakthrough therapy, Orphan drugs, Head and neck cancer, Pancreatic cancer, Cancer, Pembrolizumab, Cancer immunotherapy, NBTXR3, NANOBIOTIX:, NBTXR3, NANOBIOTIX:

In addition to the lung cancer study described above, two phase II studies, each evaluating NBTXR3 in combination with anti-PD-1 for patients with head and neck cancer (inoperable locoregional recurrent amenable to reirradiation and recurrent metastatic with limited PD-L1 expression or refractory); one phase I study evaluating NBTXR3 in combination with chemotherapy for patients with esophageal cancer; and one phase I study evaluating NBTXR3 as a single-agent activated by RT for patients with pancreatic cancer are active and enrolling.

Key Points: 
  • In addition to the lung cancer study described above, two phase II studies, each evaluating NBTXR3 in combination with anti-PD-1 for patients with head and neck cancer (inoperable locoregional recurrent amenable to reirradiation and recurrent metastatic with limited PD-L1 expression or refractory); one phase I study evaluating NBTXR3 in combination with chemotherapy for patients with esophageal cancer; and one phase I study evaluating NBTXR3 as a single-agent activated by RT for patients with pancreatic cancer are active and enrolling.
  • As previously announced, the first patient has been injected with NBTXR3 in each of the esophageal cancer and pancreatic cancer studies.
  • The first NBTXR3 injections in the phase II head and neck cancer studies are expected in the second half of 2021.
  • The clinical collaboration between Nanobiotix and MD Anderson is a collaborator-led expansion of the NBTXR3 development pipeline across indications and therapeutic combinations.

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Retrieved on: 
Thursday, June 3, 2021
Research, Technology, Clinical trials, Nanotechnology, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Medicine, Clinical medicine, Medical specialties, Immune system, Radiation therapy, Abscopal effect, Programmed cell death protein 1, Oncology, NBTXR3, NANOBIOTIX, NBTXR3, NANOBIOTIX

As of the data cut-off, 16 patients in the study received NBTXR3 plus radiotherapy and 13 were evaluable for response.

Key Points: 
  • As of the data cut-off, 16 patients in the study received NBTXR3 plus radiotherapy and 13 were evaluable for response.
  • Tumor regression was observed in 76.9% (10/13) of evaluable patients, regardless of prior anti-PD-1 exposure.
  • In patients with prior primary or secondary resistance to anti-PD-1, 75% (6/8) had tumor regression and 50% (4/8) had investigator-assessed objective response.
  • Some patients in the study showed delayed tumor response and/or abscopal effect, suggesting NBTXR3 may potentially prime an immune response.

Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board

Retrieved on: 
Tuesday, May 25, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Laurent Levy, Nanobiotix, Corporate governance, Phillips, Supervisory board, NBTXR3, NANOBIOTIX:, NBTXR3, NANOBIOTIX:

Dr. Phillips succeeds Laurent Condomine, who will retire from the supervisory board after 11 years of leadership.

Key Points: 
  • Dr. Phillips succeeds Laurent Condomine, who will retire from the supervisory board after 11 years of leadership.
  • I am truly honored and excited by my appointment as chairman of the Nanobiotix supervisory board, said Dr. Phillips.
  • I look forward to working with the board and the entire organization toward delivering the breakthrough promise of its potentially transformational technology.
  • We are pleased to welcome Dr. Gary Phillips to the Nanobiotix supervisory board at this pivotal moment for the Company, said Nanobiotix co-founder and chief executive officer Laurent Levy.